Professor Sir Martin Landray
Professor of Medicine and Epidemiology at the University of Oxford; Science Priority Lead for Clinical Trials at Health Data Research UK (HDR UK); Co-Chief Investigator of the RECOVERY trial.
Sir Martin Landray is a Professor of Medicine and Epidemiology at the University of Oxford. His work seeks to further understanding of the determinants of common diseases through the design, conduct and analysis of efficient, large-scale clinical trials and prospective cohort studies (including UK Biobank). He has led a series of major clinical trials assessing treatments for cardiovascular and kidney disease. These have enrolled over 65,000 individuals, producing results that have changed regulatory drug approvals, influenced clinical guidelines and changed prescribing practice to the benefit of patients.
Professor Sir Martin Landray is Co-Chief Investigator of the RECOVERY trial, the world’s largest COVID-19 drug trial. The trial has had more than 39,000 participants across 181 active sites.
He is heavily involved in efforts to streamline clinical trials, working with regulatory agencies to facilitate efficient and cost-effective trials. He is a member of the Steering Committee of the FDA Clinical Trial Transformation Initiative, leading the Monitoring, Quality by Design, and Mobile Clinical Trials projects. He is a member of the NHS Digital Research Advisory Group and the NICE Data & Analytics External Reference Group, and leads the 21st Century Clinical Trials programme for Health Data Research UK.
Professor Sir Martin Landray completed medical training at University of Birmingham (UK) and specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine at University of Birmingham. He continues to practise clinical medicine as an Honorary Consultant Physician in the Cardiology, Cardiac and Thoracic Surgery Directorate at Oxford University Hospitals NHS Trust. He is a Fellow of the Academy of Medical Sciences, the Royal College of Physicians of London, the Higher Education Academy, the British Pharmacological Society, and the European Society of Cardiology.
In the 2021 Queen’s Birthday Honours, he was awarded a knighthood for services to public health and science.